Home Cart Sign in  
Chemical Structure| 1032008-74-4 Chemical Structure| 1032008-74-4

Structure of Endoxifen Z-isomer HCl
CAS No.: 1032008-74-4

Chemical Structure| 1032008-74-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Endoxifen Z-isomer HCl is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast cancer cells expressing estrogen receptor-alpha (ERα). Endoxifen Z-isomer HCl inhibits hERG tail currents at 50 mV in a concentration-dependent manner with IC50 values of 1.6 μM.

Synonyms: Endoxifen HCl; Endoxifen Z-isomer hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Endoxifen Z-isomer HCl

CAS No. :1032008-74-4
Formula : C25H28ClNO2
M.W : 409.95
SMILES Code : OC1=CC=C(/C(C2=CC=C(OCCNC)C=C2)=C(C3=CC=CC=C3)\CC)C=C1.[H]Cl
Synonyms :
Endoxifen HCl; Endoxifen Z-isomer hydrochloride
MDL No. :MFCD29049515
InChI Key :RPFIMPDXTABYCN-BJFQDICYSA-N
Pubchem ID :54613017

Safety of Endoxifen Z-isomer HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H350-H360-H410
Precautionary Statements:P201-P202-P273-P280-P308+P313-P391-P405-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
Endoxifen Z-isomer hydrochloride, recognized as a pivotal Tamoxifen metabolite, plays a crucial role in delivering the anti-estrogenic effects of Tamoxifen in breast cancer cells that express estrogen receptor-alpha (ERα). It impedes hERG tail currents at 50 mV in a dose-responsive manner, with IC50 values established at 1.6 μM[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
BT20 cells >5μM 7 days Evaluate the antiproliferative activity of Z-endoxifen in ER- and HER2- breast cancer cells PMC7238733
MDAMB468 cells >5μM 7 days Evaluate the antiproliferative activity of Z-endoxifen in ER- and HER2- breast cancer cells PMC7238733
MDA-MB-231 cells 1–25 μM 48, 72, and 96 hours Inhibits PI4KIIα activity, reduces exosome secretion PMC7372867
Cyp2dKO mouse liver microsomes (MLMs) 5 μM 6 minutes PMC5193068
MDAMB231 cells >5μM 7 days Evaluate the antiproliferative activity of Z-endoxifen in ER- and HER2- breast cancer cells PMC7238733
SK-MEL-5 human melanoma cells 10 μM 48 hours To evaluate the cytotoxic effect of Endoxifen on SK-MEL-5 cells, resulting in 92.5% cell death. PMC5751858
B16F10 mouse melanoma cells 10 μM 48 hours IDF-11774 reduced HIF-1α protein expression, decreased cell survival, and increased cytotoxicity under CoCl2-induced hypoxic conditions. PMC5751858
MCF-7 cells 1–25 μM 48, 72, and 96 hours K-145 reduced nuclear S1P, almost completely blocked H3-K9ac, HIF1α associated spheroid formation, and enhanced dead cells PMC7372867
EO771 cells 1–25 μM 48, 72, and 96 hours To evaluate the sensitivity of EO771 cells to endocrine therapy, results showed that EO771 cells were sensitive to anti-estrogen drugs such as endoxifen, with significantly increased sensitivity after 96 hours. PMC7372867
TRC cells 5 µM and 10 µM 3 days To evaluate the effect of Endoxifen and PRCP inhibitor on TRC cell proliferation and death. Results showed that combination of PRCPi with endoxifen significantly inhibited proliferation and increased cell death. PMC9639567
B6-9 cells 5 µM and 10 µM 72 hours To evaluate the effect of Endoxifen and PRCP inhibitor on B6-9 cell death. Results showed that combination of PRCPi with endoxifen significantly increased cell death. PMC9639567
MCF7 cells 5 µM and 10 µM 72 hours To evaluate the effect of IKBKE overexpression on cell invasion and migration, results showed that IKBKE overexpression significantly enhanced cell invasion and migration. PMC9639567
Wild-type mouse liver microsomes (MLMs) 5 μM 6 minutes Wild-type MLMs showed 7.4-fold higher activity in generating Endoxifen compared to hCYP2D6 MLMs. PMC5193068
HCYP2D6 mouse liver microsomes (MLMs) 5 μM 6 minutes Evaluated kinetic parameters of NDT conversion to Endoxifen, showing KS1 of 5.1 μM, KS2 of 3.9 μM, and Vmax of 1128 pmol/min/mg. PMC5193068
Cells isolated from the brains of neonatal Cspg4/Tomato mice 0.5 ng/ml to 2000 ng/ml 3 days To test the ability of Endoxifen to promote recombination in Cspg4/tomato mice, EC50 of 32.1±1.6 ng/ml PMC5071318

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice MCF7AC1 tumor model Oral gavage 25 mg/kg and 75 mg/kg Once daily for 4 weeks Evaluate the antitumor activity of Z-endoxifen in AI-sensitive and AI-resistant ER+ breast cancer PMC7238733
C57BL/6 mice B16F10 melanoma model Oral 4 and 8 mg/kg body weight/day Once daily for 20 days To evaluate the anti-tumor activity of Endoxifen in the B16F10 melanoma model, showing 26.7% and 82.7% reduction in lung metastatic nodules at 4 and 8 mg/kg doses, respectively. PMC5751858
Mice CX3CR1creERT2/tdTomatofl/fl, Camk2acreERT2/tdTomatofl/fl, TMEM119creERT2/tdTomatofl/fl Intrahippocampal injection 2mg/mL (stereotaxic injection), 167ng/μL (chronic infusion) Single stereotaxic injection or chronic infusion for 1 week Delivery of endoxifen via microfluidic polymer fibers enables region-specific recombination with minimal damage to the surrounding environment. PMC10842189
NSG mice ER+ MCF7 cell tumors and ER+ human PDX tumors Intraperitoneal injection 20 mg/kg/day 5 days/week for 5 weeks To evaluate the effect of PRCP inhibitor combined with Endoxifen on ER+ tumor growth. Results showed that combined treatment significantly induced tumor regression. PMC9639567
Mice Cdk8fl/fl/Rosa-Cre-ERT2 mice Oral gavage and intraperitoneal injection 3 mg per day Once daily for 5 days To compare the efficiency of knockout activation between different administration routes, finding that intraperitoneal injection showed higher knockout efficiency in the brain compared to oral gavage PMC9694728

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.20mL

2.44mL

1.22mL

24.39mL

4.88mL

2.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories